Impact of contouring methods on pre-treatment and post-treatment dosimetry for the prediction of tumor control and survival in HCC patients treated with selective internal radiation therapy

EJNMMI Research

Table 2 Patients and tumors baseline characteristics. All values are median (Q1–Q3) or number (percentage)

	All patients (n = 48)	Resin microspheres (n = 25)	Glass microspheres (n = 23)	p
Age (y)	66 (62–73)	68 (63–74)	64 (63–72)	NS^a
Male gender	42 (88)	23 (92)	19 (83)	NS^b
Body surface area (m²)	1.9 (1.8–2.0)	1.9 (1.8–2.1)	1.9 (1.7–2)	NS^a
Cirrhosis	37 (77)	20 (80)	16 (70)	NS^b
Cause of cirrhosis
Alcohol	24 (65)	14 (56)	10 (43)	NS^b
NASH	10 (27)	7 (28)	4 (17)	NS^b
HVC	7 (19)	4 (16)	3 (13)	NS^b
HBV	2 (5)	2 (8)	0 (0)	NS^b
Hemochromatosis	2 (5)	0 (0)	2 (9)	NS^b
Child–Pugh
A5/A6	34 (92)	18 (72)	16 (70)	NS^b
B7	3 (8)	2 (8)	1 (4)	NS^b
MRI-based Liver volume (ml)	1813 (1468–2358)	1912 (1505–2308)	1800 (1436–2435)	NS^a
MRI-based Tumor volume (ml)	203 (67–545)	188 (68–312)	284 (61–738)	NS^a
SPECT threshold-based target volume (ml)	360 (205–647)	298 (202–406)	593 (414–933)	0.002^a
PET threshold-based target volume (ml)	386 (245–786)	365 (214–643)	398 (267–827)	NS^a
Tumor burden (%)	11 (5–27)	8 (5–18)	16 (5–34)	NS^a
Injected activity (GBq)	1.6 (1.1–2.6)	1.3 (1.0–1.8)	2.3 (1.4–3.3)	0.004^a

NASH non-alcoholic steatohepatitis, HBV hepatitis B virus, HCV hepatitis C virus
^aMann and Whitney test
^bχ² test